Literature DB >> 8123495

The phase of the menstrual cycle has no influence on the disease-free survival of patients with mammary carcinoma.

T Wobbes1, C M Thomas, M F Segers, P G Peer, E D Bruggink, L V Beex.   

Abstract

We evaluated the outcome of treatment for mammary carcinoma in 89 premenopausal women in relation to the phase of the menstrual cycle. The phase of the cycle was determined on the basis of serum concentrations of 17 beta-oestradiol and progesterone. The serum samples were collected 1 day prior to or on the day of operation. After a median follow-up of 4.1 years no significant differences in disease-free survival were found between the preovulatory (proliferative), periovulatory and post-ovulatory (luteal) groups. No differences in survival were found in these subgroups between the N0 and N1 subgroup. On the basis of this study we cannot confirm that the phase of the menstrual cycle during surgery has any effect on the eventual outcome in mammary carcinoma patients. However larger studies of this type are required before definitive conclusions can be reached.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8123495      PMCID: PMC1968874          DOI: 10.1038/bjc.1994.110

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Optimal timing of initial breast cancer surgery.

Authors:  W M Gregory; M A Richards; I S Fentiman
Journal:  Ann Intern Med       Date:  1992-02-01       Impact factor: 25.391

2.  Timing of breast cancer surgery in the menstrual cycle and outcome.

Authors:  J F Forbes
Journal:  Ann Oncol       Date:  1991-04       Impact factor: 32.976

3.  Menstrual influence on surgical cure of breast cancer.

Authors:  W J Hrushesky; A Z Bluming; S A Gruber; R B Sothern
Journal:  Lancet       Date:  1989-10-21       Impact factor: 79.321

4.  Menstrual history and breast cancer surgery.

Authors:  S A Gruber; K L Nichol; R B Sothern; M E Malone; J D Potter; D Lakatua; W J Hrushesky
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

5.  Assessment of unconjugated oestradiol and progesterone serum levels throughout pregnancy in normal women and in women with hyperprolactinaemia, who conceived after bromocriptine treatment.

Authors:  C M Thomas; R S Corbey; R Rolland
Journal:  Acta Endocrinol (Copenh)       Date:  1977-10

6.  Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer.

Authors:  R A Badwe; W M Gregory; M A Chaudary; M A Richards; A E Bentley; R D Rubens; I S Fentiman
Journal:  Lancet       Date:  1991-05-25       Impact factor: 79.321

7.  Breast cancer and timing of surgery during menstrual cycle. A 5-year analysis of 385 pre-menopausal women.

Authors:  M F Gnant; M Seifert; R Jakesz; A Adler; M Mittlboeck; P Sevelda
Journal:  Int J Cancer       Date:  1992-11-11       Impact factor: 7.396

8.  Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival.

Authors:  R T Senie; P P Rosen; P Rhodes; M L Lesser
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

9.  Timing of breast cancer surgery within the menstrual cycle: influence on lymph-node involvement, receptor status, postoperative metastatic spread and local recurrence.

Authors:  J C Rageth; P Wyss; C Unger; E Hochuli
Journal:  Ann Oncol       Date:  1991-04       Impact factor: 32.976

  9 in total
  3 in total

1.  Timing of surgery during the menstrual cycle and prognosis of breast cancer.

Authors:  R A Badwe; I Mittra; R Havaldar
Journal:  J Biosci       Date:  2000-03       Impact factor: 1.826

2.  Effect of timing of surgery during the menstrual cycle of premenopausal breast cancer patients.

Authors:  W Jäger; W Sauerbrei
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

3.  Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study.

Authors:  Clive S Grant; James N Ingle; Vera J Suman; Daniel A Dumesic; D Lawrence Wickerham; Richard D Gelber; Patrick J Flynn; Lorna M Weir; Mattia Intra; Wayne O Jones; Edith A Perez; Lynn C Hartmann
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.